Literature DB >> 1993627

Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy.

D J Brenner1, E J Hall.   

Abstract

Low dose rate interstitial brachytherapy is extremely useful for those tumors that are accessible for an implant, while the introduction of remote afterloaders has eliminated exposure to nursing personnel. Currently, such machines require an inventory of many sources which are loaded into catheters implanted in the tumor and kept in place during treatment. A significant simplification of such machines would be possible in a pulsed mode, with a single source moving under computer control through the catheters. Assuming that the treatment time and average dose rate are kept unchanged, the question addressed is to find those combinations of radiation pulse widths and frequencies that would be functionally equivalent to a continuous irradiation. The linear-quadratic formalism was used to reanalyze published low dose-rate studies on cells of human origin to obtain 36 parameter sets [alpha, beta, T1/2], where T1/2 is the half time for sublethal damage repair. These data are consistent with those for human tumors. For each parameter set, those combinations of pulse width and frequency were calculated that would yield a functionally equivalent cell survival. For a regimen of 30 Gy in 60 hr, a pulse width of 10 min with a period between pulses of 1 hr would be appropriate for all the cell lines considered. Similar results were found for other possible time/dose combinations. For late effects, a 1-hr period between 10-min pulses might produce up to a 2% increase in late-effect probability, which is probably acceptable for the small volumes irradiated in interstitial brachytherapy.

Entities:  

Mesh:

Year:  1991        PMID: 1993627     DOI: 10.1016/0360-3016(91)90158-z

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  28 in total

Review 1.  A review of the clinical experience in pulsed dose rate brachytherapy.

Authors:  Brian V Balgobind; Kees Koedooder; Diego Ordoñez Zúñiga; Raquel Dávila Fajardo; Coen R N Rasch; Bradley R Pieters
Journal:  Br J Radiol       Date:  2015-08-20       Impact factor: 3.039

2.  Solid tumor risks after high doses of ionizing radiation.

Authors:  Rainer K Sachs; David J Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

3.  Impact of prolonged fraction dose-delivery time modeling intensity-modulated radiation therapy on hepatocellular carcinoma cell killing.

Authors:  Xiao-Kang Zheng; Long-Hua Chen; Xiao Yan; Hong-Mei Wang
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 4.  Pulsed dose rate brachytherapy.

Authors:  A Polo
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

5.  [Effects of fractionation and dose rate in PDR brachytherapy of B14 cells].

Authors:  L Keilholz; M H Seegenschmiedt; M Lotter; R Schulz-Wendtland; J von Erffa; S Pflüger; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-02       Impact factor: 3.621

6.  Pulsed brachytherapy: a modelled consideration of repair parameter uncertainties and their influence on treatment duration extension and daytime-only "block-schemes".

Authors:  T S A Underwood; R G Dale; A M Bidmead; C A Nalder; P R Blake
Journal:  Br J Radiol       Date:  2011-01-25       Impact factor: 3.039

7.  Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.

Authors:  Robert F Hobbs; Sébastien Baechler; Richard L Wahl; Bin He; Hong Song; Caroline E Esaias; Eric C Frey; Heather Jacene; George Sgouros
Journal:  J Nucl Med       Date:  2010-02-11       Impact factor: 10.057

8.  [In vitro studies of PDR brachytherapy].

Authors:  P Fritz; C Frank; K J Weber
Journal:  Strahlenther Onkol       Date:  1998-07       Impact factor: 3.621

9.  Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.

Authors:  Robert F Hobbs; Richard L Wahl; Eric C Frey; Yvette Kasamon; Hong Song; Peng Huang; Richard J Jones; George Sgouros
Journal:  J Nucl Med       Date:  2013-08-05       Impact factor: 10.057

10.  Human Lung Cancer Risks from Radon - Part III - Evidence of Influence of Combined Bystander and Adaptive Response Effects on Radon Case-Control Studies - A Microdose Analysis.

Authors:  Bobby E Leonard; Richard E Thompson; Georgia C Beecher
Journal:  Dose Response       Date:  2010-09-10       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.